PolymarketVérifier la disponibilitéSans KYC2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
December 31, 68%+1.0pt
Qualite du marche
67 / 100
Qualité moyenneVolume 24h
1,9 k €
Liquidité
16,9 k €
Liquidité moyenneAchat / Vente
67.0% / 68.0%
Spread
1.0 pt
Spread serréComments
0
Données du marché
Mis à jour il y a 15 minutes
19 août 26, 17:4931 déc. 27, 23:59
Tendances
Règles
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
